Rate Video

ASCO 2020 | Daratumumab in the treatment of MM with high-risk cytogenetics

Luciano Costa • 11 May 2020

Multiple Myeloma Daratumumab

ALCYONE Cassiopeia MAIA

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the meta-analysis of randomized phase III trials of daratumumab in the treatment of multiple myeloma (MM) with high-risk cytogenetics. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

The management of myeloma during the COVID-19 pandemic

Luciano Costa • 12 Jun 2020

Real-world data on outcomes of t(11;14) multiple myeloma

Luciano Costa • 6 Dec 2020

Cytogenetic risk & the impact of daratumumab in myeloma

Luciano Costa • 15 Jun 2020

Refractory multiple myeloma: analyzing MAMMOTH and STORM

Luciano Costa • 3 Oct 2020

Related Videos

Treating later relapses in patients with multiple myeloma

Stefan Knop • 12 Apr 2021

Treating MGRS and MGUS with neuropathy

Stefan Knop • 12 Apr 2021

Elotuzumab, pomalidomide, and dexamethasone for advanced myeloma

Stefan Knop • 12 Apr 2021

Novel immunotherapies for multiple myeloma

Daniel Auclair • 8 Apr 2021